Session Chair Profile
B.S., VP, Agilent Technologies
Biography
Allison Ballmer is VP at Agilent’s Diagnostics and Genomics Group where she is responsible for strategy and corporate development. Allison recently served as International Business Leader at Roche Molecular Systems where she led all aspects of portfolio and strategy to advance Next Generation Sequencing platforms into the clinic. Allison has enjoyed a 15-year career in Cancer Diagnostics, spanning translational medicine to companion diagnostics. She led Global Marketing and Commercialization for the Swiss-based Molecular Diagnostics arm of Biocartis. She held various Business Development and Commercial leadership roles at Roche and began her career at Ventana Medical Systems in Quality, Regulatory and Operations Management. Allison earned her B.S. in Mechanical Engineering from Virginia Tech, and Strategy and Marketing certifications from London Business School and Cornell University. Allison also serves as a Board Director at Mission Bio, a precision medicine single cell genomics company.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: Genome sequencing is now a sufficiently mature and affordable technology for clinical use. Its application promises not only to transform clinicians’ diagnostic and predictive ability, but also to improve preventative therapies, monitor response to therapy, and tailor patient treatment to an individual’s genetic make-up. However, this is not coming without the challenges of adapting existing regulatory, reimbursement and care pathways.
